Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy

American Journal of Health-System Pharmacy

Volumn 59, Issue 19, 2002, Pages 1837-1846

  Lachaine, Jean ^a   Laurier, Claudine ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antiemetics; Antineoplastic agents; Costs; Dosage schedules; Economics; Nausea; Ondansetron; Steroids, cortico ; Toxicity; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; BROMAZEPAM; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; LORAZEPAM; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOXANTRONE; ONDANSETRON; PREDNISOLONE; PROCHLORPERAZINE; VINCRISTINE;

ARTICLE; CALCULATION; CANADA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DEVICE; ECONOMIC ASPECT; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036789822     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.19.1837     Document Type: Article

References (87)

1. Ballatori E, Roila F, Berto P et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics. 1994; 5:227-37.
2. Becker AJ, Mutnick A, Ross MB et al. Combining a clinical trial with decision analysis to evaluate antiemetic agents. Formulary. 1996; 31:670-83.
3. Buxton MJ, O'Brien BJ. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Cancer. 1992; 19(suppl):S64-7.
4. Cunningham D, Gore M, Davidson N et al. The real costs of emesis-an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer. 1993; 29A:303-6.
5. Sands R, Roberts JT, Marsh M et al. Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis. Clin Oncol. 1992; 4:67-8.
6. Tanneberger S, Lelli G, Martoni A et al. The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). J Chemother. 1992; 4:326-31.
7. Zbrozek AS, Cantor SB, Cardenas MP et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm. 1994; 51:1555-63.
8. Barrajon E, de las Penas R. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Support Care Cancer. 2000; 8:323-33.
9. Johnson NE, Nash DB, Carpenter CE et al. Ondansetron: costs and resource utilisation in a US teaching hospital setting. Pharmacoeconomics. 1993; 3:471-81.
10. Jones AL, Lee G, Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer. 1993; 29A:51-6.
11. Dranitsaris G, Warr D, Puodziunas A. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer. 1995; 3:183-9.
12. Cox F, Hirsch J. Ondansetron: a cost-effective advance in anti-emetic therapy. Oncology. 1993; 50:186-90.
13. Lachaine J, Laurier C, Langleben A et al. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Crit Rev Oncol Hematol. 1999; 32:105-12.
14. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992; 49:295-304.
15. Consultative Council of Pharmacologie. [Treatment of nausea and vomiting induced by radiotherapy and chemotherapy]. Quebec: Quebec Government, 1993. In French.
16. Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 1993; 118:407-13.
17. Beck TM. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs. 1995; 6:237-42.
18. Dicato MA, Kaasa S, Campora E et al. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. Clin Oncol. 1992; 4:275-9.
19. Pater JL, Lofters WS, Zee B et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997; 8:181-5.
20. Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. Eur J Cancer Clin Oncol. 1989; 25(suppl 1):S35-9.
21. Soukop M. Management of cyclophosphamide-induced emesis over repeat courses. Oncology. 1996; 53(suppl 1):39-45.
22. Berry WR, House KW, Lee JT et al. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. Semin Oncol. 1992; 19(6, suppl 15):33-7.
23. Harousseau JL, Zittoun R, Bonneterre J et al. [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination.] Bull Cancer. 2000; 87:491-7. In French.
24. Evans C, Stein RC, Davenport J et al. Comparison of ondansetron with dexamethasone and domperidone in the prophylaxis of non-cisplatin chemotherapy induced emesis refractory to dexamethasone. Eur J Cancer. 1991; 27:302-3.
25. Harvey VJ, Evans BD, Mitchell PL et al. Reduction of carboplatin induced emesis by ondansetron. Br J Cancer. 1991; 63: 942-4.
26. Seynaeve C, de Mulder PH, Lane-Allman E et al. The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin Oncol. 1991; 3:199-203.
27. De Wit R, Beijnen JH, van Tellingen O et al. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. Br J Cancer. 1996; 74:323-6.
28. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997; 15:2966-73.
29. Quetin P, Vacque D, Andres E et al. [Ondansetron in the prevention of vomiting induced by chemotherapy.] Sem Hop. 1997; 73:31-2. In French.
30. Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000; 342: 1554-9.
31. Barrenetxea G, Schnieder J, Centeno M et al. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol. 1996; 38:471-5.
32. Buser KS, Joss RA, Piquet D et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol. 1993; 4:475-9.
33. Bonneterre J, Chevallier B, Metz R et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol. 1990; 8:1063-9.
34. Markman M, Kennedy A, Webster K et al. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy. Gynecol Oncol. 2000; 78: 43-6.
35. Cleri LB, Kris MG, Tyson LB et al. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cancer. 1995; 76:774-8.
36. Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ et al. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. J Chemother. 1996; 8:315-8.
37. Campora E, Oliva C, Mammoliti S et al. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. Breast Cancer Res Treat. 1991; 19:129-32.
38. Campora E, Giudici S, Merlini L et al. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am J Clin Oncol. 1994; 17:522-6.
39. Chiara S, Campora E, Simoni C et al. Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment. Anticancer Res. 1995; 15:1597-9.
40. Coiffier B, Khayat D, Misset JL et al. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy.] Bull Cancer. 1997; 84: 781-7. In French.
41. Cubeddu LX, Hoffman IS, Fuenmayor NT et al. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol. 1990; 8:1721-7.
42. Fauser AA, Duclos B, Chemaissani A et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer. 1996; 32A:1523-9.
43. Framarino dei Malatesta M, Veneziano M, Fiorelli C et al. Ondansetron in chemotherapy-induced emesis. Our experience. Eur J Gynaecol Oncol. 1995; 16:97-106.
44. Fraschini G, Ciociola A, Esparza L et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991; 9:1268-74.
45. Goldschmidt H, Salwender H, Egerer G et al. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Anticancer Drugs. 1997; 8:436-44.
46. Hesketh PJ, Beck T, Uhlenhopp M et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995; 13:2117-22.
47. Huc P, Block S, Carlier D et al. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies.] Bull Cancer. 1998; 85:562-8. In French.
48. Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol. 1992; 31:573-5.
49. Jantunen IT, Muhonen TT, Kataja VV et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapya randomised study. Eur J Cancer. 1993; 29A:1669-72.
50. Jantunen IT, Flander MK, Heikkinen MI et al. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by noncisplatin containing chemotherapy. Acta Oncol. 1993; 32:413-5.
51. Markman M, Kennedy A, Webster K et al. Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. J Cancer Res Clin Oncol. 1997; 123:224-6.
52. Massidda B, Ionta MT. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. J Chemother. 1996; 8:237-42.
53. Park JO, Rha SY, Yoo NC et al. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol. 1997; 20:569-72.
54. Poon RT, Chow LW. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. Br J Cancer. 1998; 77:1683-5.
55. Ribiero MM, de Faria L, dos RF et al. Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Anticancer Drugs. 1993; 4(suppl 2):23-7.
56. Rosso R, Campora E, Cetto G et al. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res. 1991; 11:937-9.
57. Yalcin S, Tekuzman G, Baltali E et al. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am J Clin Oncol. 1999; 22:94-6.
58. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol. 1992; 19(6, suppl 15):20-5.
59. Beck TM, York M, Chang A et al. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest. 1997; 15: 297-303.
60. Bonneterre J, Hecquet B. (Granisetron (i.v.) compared with ondansetron (i.v. plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.] Bull Cancer. 1995; 82: 1038-43. In French.
61. Clavel M, Bonneterre J, d'Allens H et al. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer. 1995; 3lA: 15-9.
62. Crucitt MA, Hyman W, Grote T et al. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin Ther. 1996; 18:778-88.
63. Cubeddu LX, Pendergrass K, Ryan T et al. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol. 1994; 17:137-46.
64. Davidson NG, Paska W, Van Belle S et al. Ondansetron suppository: a randomised, double-blind, double-dummy, parallelgroup comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. Oncology. 1997; 54:380-6.
65. Davidson N, Rapoport B, Erikstein B et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Clin Ther. 1999; 21:492-502.
66. DiBenedetto J, Cubeddu LX, Ryan T et al. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther. 1995; 17:1091-8.
67. Dicato MA. Oral treatment with ondansetron in an outpatient setting. Eur J Cancer. 1991; 27(suppl 1):S18-9.
68. Du Bois A, Vach W, Cramer-Giraud U et al. Pattern of carboplatin-induced emesis. Anticancer Drugs. 1995; 6:645-51.
69. Du Bois A, McKenna CJ, Andersson H et al. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology. 1997; 54:7-14.
70. Gebbia V, Cannata G, Testa A et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994; 74:1945-52.
71. Herrstedt J, Sigsgaard T, Boesgaard M et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med. 1993; 328: 1076-80.
72. Janinis J, Giannakakis T, Athanasiades A et al. A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. Tumori. 2000; 86:37-41.
73. Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet. 1991; 338:483-7.
74. Jorgensen M, Victor MA. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Acta Oncol. 1996; 35:159-63.
75. Kaasa S, Kvaloy S, Dicato MA et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer. 1990; 26:311-4.
76. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994; 12:1050-7.
77. Levitt M, Warr D, Yelle L et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med. 1993; 328:1081-4.
78. Mabro M, Kerbrat P, Granisetron Study Group. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer.] Bull Cancer. 1999; 86:295-301. In French.
79. Marschner NW, Adler M, Nagel GA et al. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer. 1991; 27:1137-40.
80. Meden H, Meissner O, Conrad A et al. Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Eur J Gynaecol Oncol. 1996; 17:114-22.
81. Mughal TI. Efficacy of ondansetron and lorazepam in controlling emesis associated with cytotoxic chemotherapy. Acta Oncol. 1994; 33:537-9.
82. Perez EA, Hesketh P, Sandbach J et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998; 16:754-60.
83. Perez EA, Lembersky B, Kaywin P et al. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am. 1998; 4:52-8.
84. Smith DB, Rustin GJ, Howells N et al. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. Ann Oncol. 1991; 2:607-8.
85. Stewart A, McQuade B, Cronje JD et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamideinduced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology. 1995; 52:202-10.
86. Tsavaris NB, Koufos C, Katsikas M et al. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy. J Pain Symptom Manage. 1999; 18:218-22.
87. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics. 1996; 9:113-20.